Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 18/20 | 0.85 |
| ▸ | ESRRB | O95718 | 1/20 | 0.85 |
| ▸ | ESR1 | P03372 | 1/20 | 0.85 |
| ▸ | ESRRG | P62508 | 1/20 | 0.85 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380997 | 1.00 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8156842 | 1.00 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648931 | 0.94 | ESRRA (0.79) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648930 | 0.94 | ESRRA (0.79) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8163017 | 0.94 | ESRRA (0.79) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8164211 | 0.93 | ESRRA (0.78) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2381958 | 0.93 | ESRRA (0.78) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2383285 | 0.93 | ESRRA (0.81) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8158706 | 0.93 | ESRRA (0.78) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL12299736 | 0.93 | ESRRA (0.78) | ESRRAESRRBESR1ESRRGESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344009-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-á modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-01 | — | — | US | disclosed |
| US-20110237625-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS | JANSSEN PHARAMCEUTICA N.V. (BE) | 2011-09-29 | — | — | US | disclosed |
| US-7846953-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2010-12-07 | — | — | US | disclosed |
| EP-2129668-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2009-12-09 | — | — | EP | disclosed |
| US-20090111855-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2008109727-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237625-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS | ESR2, ESRRA, ESRRB | ESRRA 2/4885ESRRB 3/4885ESR1 6/4885 |
| US-20090111855-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.